Skip to content

Effect of Dietary Glycemic Index on Beta-cell Function

Effect of Dietary Glycemic Index on Beta-cell Function

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01386645
Acronym
GIdiet
Enrollment
56
Registered
2011-07-01
Start date
2011-07-31
Completion date
2019-08-01
Last updated
2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Fasting Glucose, Impaired Glucose Tolerance, Oxidative Stress, Prediabetes

Keywords

impaired glucose tolerance, prediabetes, dietary glycemic index, beta-cell function, insulin secretion, oxidative stress, glycemic variability

Brief summary

The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for developing type 2 diabetes. Furthermore, the study will determine whether changes in beta-cell function are associated with glycemic variability and whether they are mediated by oxidative stress. To decrease or increase glycemic variability the study will provide subjects with special diets containing either low or high glycemic index foods respectively for 4 weeks. To determine if oxidative stress is a mediator, subjects on the high glycemic index diet will take either placebo or the anti-oxidant N-acetylcysteine. The study will address the hypothesis that increased glycemic variability results in increased oxidative stress and thereby exacerbates beta-cell dysfunction in individuals with impaired glucose tolerance and/or impaired fasting glucose. The findings may have important implications for the development of effective strategies aimed at the prevention and treatment of type 2 diabetes. In addition, understanding the contribution of dietary glycemic index to beta-cell dysfunction in subjects with pre-diabetes may have a significant public health impact, including changes to dietary counseling and promotion of healthier eating patterns.

Detailed description

Type 2 diabetes is a major health problem in the United States affecting millions of people. It is caused by failure of the pancreatic beta-cells to secrete enough insulin resulting in high blood glucose levels. People with impaired glucose tolerance (IGT) and impaired fasting glucose have elevated glucose levels and are at increased risk for progressing to type 2 diabetes. The long-term objectives of this research are to better understand the factors that contribute to the loss of beta-cell function and impaired insulin secretion. High glucose levels have been shown to impair beta-cell function by causing oxidative stress, and oscillating high glucose levels increase oxidative stress even more than continuous high glucose. Diets containing foods with a high glycemic index (GI) increase the glycemic load (GL) of the diet and post-prandial glucose levels. Therefore, high GL (HGL) diets could be potentially damaging to the beta-cell by increasing glucose fluctuations and oxidative stress. Conversely, low GL (LGL) diets may be beneficial. The study explores the hypothesis that increased glycemic variability results in increased oxidative stress and thereby exacerbates beta-cell dysfunction in people with pre-diabetes. Specific Aim 1: Determine if a HGL diet worsens and a LGL diet improves beta-cell function compared to a baseline control diet in subjects with pre-diabetes. Specific Aim 2: Determine if increased glycemic variability on the HGL diet is associated with decreased beta-cell function and conversely if decreased glycemic variability on the LGL diet is associated with improved beta-cell function in subjects with pre-diabetes. Specific Aim 3: Determine if oxidative stress induced by a HGL diet mediates decreases in beta-cell function by determining if 1) systemic markers of oxidative stress are associated with beta-cell function; 2) if the relationship between glycemic variability and beta-cell function is at least partially explained by oxidative stress; and 3) the anti-oxidant N-acetylcysteine (NAC) prevents decreases in beta-cell function on a HGL diet. Study design: The study will be a randomized, parallel-design feeding study in men and women with pre-diabetes. Subjects will be randomly assigned to one of 3 separate arms (n=20/arm): 1) 4 weeks on a LGL diet (GI\<35); 2) 4 weeks on a HGL diet (GI\>70) + placebo twice daily; or 3) 4 weeks on a HGL diet (GI\>70) + NAC 1200 mg twice daily. Subjects will be studied after a 2 week baseline control diet with a moderate glycemic load (GI 55-58) for comparison and all diets will be weight stable with the same macronutrient composition (55% carbohydrate/30% fat/15% protein). Beta-cell function will be assessed by both a frequently sampled intravenous glucose tolerance test and a meal test. Glycemic variability will be assessed by a Continuous Glucose Monitoring System and glycemic control by fructosamine. Markers of oxidative stress will be measured.

Interventions

Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab

OTHERhigh glycemic index (HGI) diet plus placebo (PLAC)

Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.

DRUGhigh glycemic index diet plus N-acetylcysteine

Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.

Sponsors

VA Puget Sound Health Care System
CollaboratorFED
Seattle Institute for Biomedical and Clinical Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* impaired glucose tolerance (2 hour glucose 140-200 mg/dl after a standard 75 grams oral glucose tolerance test \[OGTT\]) or * fasting glucose 100-115 mg/dl and 2 hour glucose \> 100 mg/dl after a standard OGTT

Exclusion criteria

* diabetes or taking diabetes medications * fasting glucose \>115 mg/dl * alanine aminotransferase (ALT) \>1.5 times the upper limit of normal * hematocrit \<33% * serum creatinine \>1.5 men or \>1.3 women * multiple food allergies or intolerances * other serious medical or inflammatory conditions * pregnancy or lactation * smoke or use tobacco * take medications that affect insulin sensitivity and secretion (niacin, diabetes medications or glucocorticoids) or inflammation (anti-inflammatories such as ibuprofen, naprosyn, aspirin) * significant gastroesophageal reflux (heartburn), swallowing problems or stomach ulcers, including those taking medication for these indications * taking or having taken another investigational drug within the past 30 days

Design outcomes

Primary

MeasureTime frameDescription
Disposition Index4 weeksThe disposition index generated from an intravenous glucose tolerance test (insulin sensitivity x the acute insulin response to intravenous glucose) is a measure of beta-cell function.

Secondary

MeasureTime frameDescription
Urine F2alpha Isoprostanes4 weeksFasting urine F2alpha isoprostane/Cr ratio. Urine isoprostanes were measured by ELISA (Oxford Biomedical Research).
Glycemic Variability4 weeksGlycemic variability as measured by the standard deviation (SD) of the glucose levels from the iPro continuous glucose monitoring system (CGMS)

Countries

United States

Participant flow

Participants by arm

ArmCount
Low GI Diet
low glycemic index diet low glycemic index diet: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
18
High GI Diet Placebo
high glycemic index diet plus placebo high glycemic index diet plus placebo: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
18
High GI Diet NAC
high glycemic index diet plus N-acetylcysteine high glycemic index diet plus N-acetylcysteine: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
17
Total53

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyPhysician Decision001
Overall StudyWithdrawal by Subject011

Baseline characteristics

CharacteristicLow GI DietHigh GI Diet PlaceboHigh GI Diet NACTotal
Age, Continuous57.2 years
STANDARD_DEVIATION 7
50.6 years
STANDARD_DEVIATION 10.3
51.2 years
STANDARD_DEVIATION 11
53.0 years
STANDARD_DEVIATION 9.9
BMI32.5 kg/m^2
STANDARD_DEVIATION 4.7
32.4 kg/m^2
STANDARD_DEVIATION 6.4
32.7 kg/m^2
STANDARD_DEVIATION 8
32.5 kg/m^2
STANDARD_DEVIATION 6.3
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants3 Participants2 Participants8 Participants
Race (NIH/OMB)
Black or African American
2 Participants4 Participants8 Participants14 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
13 Participants11 Participants7 Participants31 Participants
Region of Enrollment
United States
18 participants18 participants17 participants53 participants
Sex: Female, Male
Female
8 Participants9 Participants10 Participants27 Participants
Sex: Female, Male
Male
10 Participants9 Participants7 Participants26 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 180 / 180 / 17
other
Total, other adverse events
1 / 181 / 180 / 17
serious
Total, serious adverse events
0 / 180 / 180 / 17

Outcome results

Primary

Disposition Index

The disposition index generated from an intravenous glucose tolerance test (insulin sensitivity x the acute insulin response to intravenous glucose) is a measure of beta-cell function.

Time frame: 4 weeks

Population: 1 participant in the LGI group ate before the second IVGTT and was excluded. One participant in the HGI/PLAC group could not get a second IV and we were unable to perform the IVGTT.

ArmMeasureValue (MEDIAN)
Low GI DietDisposition Index708 unitless
High GI Diet PlaceboDisposition Index793 unitless
High GI Diet NACDisposition Index791 unitless
Secondary

Glycemic Variability

Glycemic variability as measured by the standard deviation (SD) of the glucose levels from the iPro continuous glucose monitoring system (CGMS)

Time frame: 4 weeks

Population: Adults with prediabetes with useable iPro CGMS data after the 4 week intervention.

ArmMeasureValue (MEAN)Dispersion
Low GI DietGlycemic Variability14.20 mg/dlStandard Error 1.03
High GI Diet PlaceboGlycemic Variability19.67 mg/dlStandard Error 1.57
High GI Diet NACGlycemic Variability17.69 mg/dlStandard Error 1.56
Secondary

Urine F2alpha Isoprostanes

Fasting urine F2alpha isoprostane/Cr ratio. Urine isoprostanes were measured by ELISA (Oxford Biomedical Research).

Time frame: 4 weeks

Population: Adults with prediabetes after 4 weeks on study interventions.

ArmMeasureValue (MEDIAN)
Low GI DietUrine F2alpha Isoprostanes2.51 ng/mg
High GI Diet PlaceboUrine F2alpha Isoprostanes3.35 ng/mg
High GI Diet NACUrine F2alpha Isoprostanes3.43 ng/mg

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026